Display options
Cite
Jia Y, Zhang C, Hua M, et al. Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncol Lett. 2017;14(6):7031-7044doi: 10.3892/ol.2017.7177.
Jia, Y., Zhang, C., Hua, M., Wang, M., Chen, P., & Ma, D. (2017). Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncology letters, 14(6), 7031-7044. https://doi.org/10.3892/ol.2017.7177
Jia, Yan, et al. "Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia." Oncology letters vol. 14,6 (2017): 7031-7044. doi: https://doi.org/10.3892/ol.2017.7177
Jia Y, Zhang C, Hua M, Wang M, Chen P, Ma D. Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncol Lett. 2017 Dec;14(6):7031-7044. doi: 10.3892/ol.2017.7177. Epub 2017 Oct 12. PMID: 29344132; PMCID: PMC5754918.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Dec;14(6):7031-7044. doi: 10.3892/ol.2017.7177. Epub 2017 Oct 12.

Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia.

Oncology letters

Yan Jia, Chen Zhang, Mingqiang Hua, Min Wang, Ping Chen, Daoxin Ma

Affiliations

  1. Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
  2. Department of Hematology, Jining First People's Hospital, Jining, Shandong 272111, P.R. China.
  3. Department of Hematology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, P.R. China.

PMID: 29344132 PMCID: PMC5754918 DOI: 10.3892/ol.2017.7177

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy in which the immune response serves a pivotal role in progression. Aryl hydrocarbon receptor (AHR) is involved in the modulation of the immune system, particularly in the differentiation of T-helper cell (Th) subsets. Although the NLR family pyrin domain-containing 3 (NLRP3) inflammasome has been implicated as essential in the pathogenesis of autoimmune and inflammatory diseases, the role it serves in the development of AML remains unknown. Therefore, in order to identify and describe the possible roles of AHR, as well as NLRP3 inflammasome, in the pathogenesis of AML and their relationship with Th subsets (Th1 Th22), the present study investigated the mRNA expression levels of AHR and NLRP3 inflammasome molecules in the peripheral blood and bone marrow. Concentrations of plasma IL-18 were also investigated in peripheral blood by ELISA, as well as the proportions of Th22 and Th1. In the present study, there were three groups: Newly diagnosed (ND) patients; complete remission (CR); and normal controls. A markedly increased expression of NLRP3 inflammasome molecules in bone marrow mononuclear cells (BMMCs) from newly diagnosed (ND) patients compared with patients in complete remission (CR) was identified. NLRP3 inflammasome molecules were also observed to be aberrantly expressed in peripheral blood (PB) mononuclear cells (PBMCs), accompanied with aberrant interleukin (IL)-18 levels in PB plasma. The relative level of IL-18 mRNA became normal after the ND patients with AML achieved CR. In bone marrow, the expression of AHR was significantly higher in ND patients than in CR patients. Furthermore, the expression level of NLRP3 inflammasome molecules was significantly correlated with AHR expression in patients with AML. In the Th subsets, a significantly increased proportion of Th22 in PB from ND patients compared with CR patients or controls was identified, accompanied with decreased Th1. It was concluded that the NLRP3 inflammasome, associated with AHR, was involved in the development of AML and may have influenced the differentiation of Th subsets.

Keywords: IL-18; NLRP3; T-helper cells; Th1; Th22; cytokine; inflammasome

References

  1. Front Pharmacol. 2015 Nov 05;6:262 - PubMed
  2. Lab Invest. 2014 Jan;94(1):52-62 - PubMed
  3. Chin J Cancer Res. 2014 Apr;26(2):135-41 - PubMed
  4. J Clin Invest. 2012 Mar;122(3):1082-96 - PubMed
  5. Nutr Rev. 2013 Jun;71(6):353-69 - PubMed
  6. Nat Commun. 2014 Aug 20;5:4738 - PubMed
  7. Biomed Res Int. 2014;2014:520763 - PubMed
  8. Curr Opin Immunol. 2014 Apr;27:1-7 - PubMed
  9. Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38 - PubMed
  10. Clin Sci (Lond). 2014 Feb;126(3):233-41 - PubMed
  11. Nature. 2008 May 1;453(7191):65-71 - PubMed
  12. Ann N Y Acad Sci. 2014 Jun;1319:82-95 - PubMed
  13. Methods. 2001 Dec;25(4):402-8 - PubMed
  14. Int J Mol Sci. 2014 Jun 05;15(6):10116-35 - PubMed
  15. Ann Rheum Dis. 2009 Apr;68(4):604-6 - PubMed
  16. Cancer Immunol Res. 2017 Feb;5(2):94-99 - PubMed
  17. Leukemia. 2008 Oct;22(10):1963-6 - PubMed
  18. Nat Med. 2007 Mar;13(3):242-4 - PubMed
  19. Oncotarget. 2016 Sep 6;7(36):58181-58192 - PubMed
  20. Nature. 2010 Apr 29;464(7293):1367-70 - PubMed
  21. Mol Immunol. 2015 Feb;63(2):521-9 - PubMed
  22. J Immunol. 2005 Dec 1;175(11):7348-56 - PubMed
  23. Inflamm Bowel Dis. 2011 May;17(5):1149-62 - PubMed
  24. J Inflamm Res. 2015 Jan 16;8:15-27 - PubMed
  25. PLoS One. 2012;7(12):e51339 - PubMed
  26. Int Immunol. 2014 Feb;26(2):61-9 - PubMed
  27. Rheumatology (Oxford). 2011 Aug;50(8):1366-72 - PubMed
  28. J Immunol. 2009 Jul 15;183(2):787-91 - PubMed
  29. Rheumatology (Oxford). 2008 Sep;47(9):1317-22 - PubMed
  30. BMC Cancer. 2015 Oct 16;15:717 - PubMed
  31. Int J Mol Sci. 2014 Jan 27;15(2):1927-45 - PubMed
  32. J Clin Oncol. 1990 May;8(5):813-9 - PubMed
  33. Pharmacol Ther. 2014 Jul;143(1):24-33 - PubMed
  34. Mol Cell Biochem. 2011 Jul;353(1-2):41-6 - PubMed
  35. Ann Rheum Dis. 2014 Jun;73(6):1202-10 - PubMed
  36. Chem Biol Interact. 2010 Mar 19;184(1-2):16-20 - PubMed
  37. J Immunol. 2010 Jul 15;185(2):974-81 - PubMed
  38. Hum Immunol. 2012 Jun;73(6):629-35 - PubMed
  39. Anticancer Res. 2009 Nov;29(11):4657-64 - PubMed
  40. Clin Chim Acta. 2013 Nov 15;426:108-13 - PubMed
  41. Curr Opin Oncol. 2017 Jan;29(1):35-40 - PubMed

Publication Types